Hipp Julian, Hillebrecht Hans Christian, Kalkum Eva, Klotz Rosa, Kuvendjiska Jasmina, Martini Verena, Fichtner-Feigl Stefan, Diener Markus K
Department of General and Visceral Surgery, Medical Centre-University of Freiburg, Germany.
Study Centre of the German Society of Surgery (SDGC), University of Heidelberg, Germany.
Surgery. 2023 Apr;173(4):957-967. doi: 10.1016/j.surg.2022.11.018. Epub 2022 Dec 19.
To compare proximal gastrectomy with double-tract reconstruction and total gastrectomy in patients with gastroesophageal junction (AEG II-III) and gastric cancer.
We conducted systematic searches in Medline, Web of Science, and Cochrane Library until December 20, 2021 (PROSPERO registration number: CRD42021291500). Risk of bias was assessed using the revised Cochrane risk of bias tool and the ROBINS-I tool, as applicable. Evidence was rated by the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach.
One randomized controlled trial (RCT) and 13 non-RCTs with 1,317 patients (715 patients with total gastrectomy and 602 patients with proximal gastrectomy with double-tract reconstruction) were included. Patients treated by total gastrectomy had a significantly higher proportion of advanced cancer stages International Union Against Cancer IB-III (odds ratio: 0.68, 95% confidence interval: 0.51-0.91, P = .01). This heterogeneity biases the observed improved overall survival of patients after proximal gastrectomy with double-tract reconstruction (odds ratio: 0.67, 95% confidence interval: 0.44-1.01, P = .05). Both procedures were comparably efficient regarding perioperative parameters. Postoperative/preoperative bodyweight ratio (mean difference: 3.56, 95% confidence interval: 1.32-5.79, P = .002), postoperative/preoperative serum-hemoglobin ratio (mean difference 3.73, 95% confidence interval: 1.59-5.88, P < .001), and postoperative serum vitamin B levels (mean difference 42.46, 95% confidence interval: 6.37-78.55, P = .02) were superior after proximal gastrectomy with double-tract reconstruction, while postoperative/preoperative serum-albumin ratio (mean difference 1.24, 95% confidence interval: -4.76 to 7.24, P = .69) and postoperative/preoperative serum total protein ratio (mean difference 1.12, 95% confidence interval: -2.77 to 5.00, P = .57) were not different. Health-related quality of life data were reported in only 2 studies, which found no significant advantages for proximal gastrectomy with double-tract reconstruction.
Proximal gastrectomy with double-tract reconstruction offers advantages in postoperative nutritional parameters compared to total gastrectomy (GRADE: moderate quality of evidence). Oncological effectiveness of proximal gastrectomy with double-tract reconstruction cannot be assessed (GRADE: very low quality of evidence). Further thoroughly planned randomized controlled trials in Western patient cohorts are necessary to improve treatment for gastric cancer patients.
比较胃食管交界部(AEG II-III)癌和胃癌患者行近端胃切除术加双通道重建与全胃切除术的疗效。
截至2021年12月20日,我们在Medline、Web of Science和Cochrane图书馆进行了系统检索(PROSPERO注册号:CRD42021291500)。根据适用情况,使用修订后的Cochrane偏倚风险工具和ROBINS-I工具评估偏倚风险。证据采用推荐分级评估、制定和评价(GRADE)方法进行分级。
纳入1项随机对照试验(RCT)和13项非RCT,共1317例患者(715例行全胃切除术,602例行近端胃切除术加双通道重建)。接受全胃切除术的患者中,国际抗癌联盟(UICC)IB-III期晚期癌症的比例显著更高(比值比:0.68,95%置信区间:0.51-0.91,P = 0.01)。这种异质性使观察到的近端胃切除术加双通道重建患者总体生存率的改善产生偏倚(比值比:0.67,95%置信区间:0.44-1.01,P = 0.05)。两种手术在围手术期参数方面效率相当。近端胃切除术加双通道重建术后/术前体重比(平均差:3.56,95%置信区间:1.32-5.79,P = 0.002)、术后/术前血清血红蛋白比(平均差3.73,95%置信区间:1.59-5.88,P < 0.001)和术后血清维生素B水平(平均差42.46,95%置信区间:6.37-78.55,P = 0.02)更高,而术后/术前血清白蛋白比(平均差1.24,95%置信区间:-4.76至7.24,P = 0.69)和术后/术前血清总蛋白比(平均差1.12,95%置信区间:-2.77至5.00,P = 0.